Dr. Menefee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
CA-60
Cleveland, OH 44195Phone+1 216-445-7920Fax+1 216-444-9464
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2002 - 2006
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
- Meharry Medical CollegeClass of 1999
Certifications & Licensure
- MD State Medical License 2004 - 2025
- OH State Medical License 2023 - 2025
- DC State Medical License 2002 - 2024
- FL State Medical License 2000 - 2022
- GA State Medical License 2014 - 2017
- MN State Medical License 2006 - 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Start of enrollment: 2009 Feb 01
- Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer Start of enrollment: 2009 Nov 03
- Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer Start of enrollment: 2010 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsAn International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid CancerKeith C. Bible, Michael E. Menefee, Chia Chi Josh Lin, Michael Millward, William J. Maples
Thyroid. 2020-09-08 - 85 citationsCabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International T...Maria E. Cabanillas, Jonas A. De Souza, Susan Geyer, Lori J. Wirth, Michael E. Menefee
Journal of Clinical Oncology. 2017-08-17 - 46 citationsReexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant CancersSimon J. Cooper, Christina A. von Roemeling, Kylie H Kang, Laura A. Marlow, Stefan K.G. Grebe
Molecular Cancer Therapeutics. 2012-07-23
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: